Furthermore, recent studies have shown that the expression levels of PD-1 and Programmed cell Death Ligand 1 (PD-L1) can be regulated by epigenetic, transcriptional, and post-transcriptional systems, which, in turn, impact tumor immunity [4,5]. This evidence concerns the gene PDCD1 and neoplasm.